Fludarabine
Childhood Renal Cell Carcinoma
Fred Hutchinson Cancer CenterSmall moleculePhase 1/2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Childhood Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Children's Oncology Group | Phase 2 | B |
DACTINOMYCIN Children's Oncology Group | Phase 2 | B |
Irinotecan Children's Oncology Group | Phase 2 | B |
VINCRISTINE SULFATE Children's Oncology Group | Phase 2 | B |
Carboplatin Children's Oncology Group | Phase 2 | B |
View all 9 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →